Abstract 1447
Background
Pim-1 is an oncogene and has been proved to play pivotal role in proliferation, apoptosis and angiogenesis. Thyroid cancer represents the most common malignancy in the endocrine system and displays a marked increase in the incidence in recent years. Papillary thyroid cancer (PTC) is among the most frequent thyroid malignancies and accounts for more than 85%. Therefore, it is worthwhile to discuss the function of Pim-1 in the development and progression of PTC.
Methods
Gene set enrichment analysis (GSEA) of Pim-1 in the PTC was performed on the TCGA databases. 177 PTC paraffin blocks were selected to make the tissue microarrays and the levels of Pim-1 protein was investigated by immunohistochemistry. Meanwhile, one of the Pim-1 kinase inhibitor, SGI-1776, was used to evaluate the function of Pim-1 on the PTC cell BCPAP and TPC-1. CCK-8 and colony formation assay was carried out to measure the cell proliferation. Apoptosis rate and migration capacity were determined by flow cytometry and wound-healing methods respectively.
Results
GSEA results revealed that Pim-1 expression was significantly associated with the immune system of PTC. IHC result showed that Pim-1 was overexpressed in the PTC tissues compared with normal adjacent tissues. Meanwhile, Pim-1 had a significant relationship with the T-stage, lymph node involvement, capsule invasion and gender. Female patients and patients with higher T-stage, positive lymph node involvement, positive capsule invasion have a higher Pim-1 level. After SGI-1776 treatment, Pim-1 expressions were obviously downregulated in both BCPAP and TPC-1. Decreased Pim-1 led to the proliferation depression, apoptosis rate elevation and the migration capacity reduction in both cell lines.
Conclusions
Taken together, our current data showed the important role of Pim-1 in the tumorigenesis of PTC. High Pim-1 level linked to immune status and aggressive malignant behavior of PTC. It was also suggested that PIM-1 kinase might be a novel molecular biomarker of PTC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Zhejiang Province Natural Science Foundation of China.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1242 - Monalizumab in combination with cetuximab in patients (pts) with recurrent or metastatic (R/M) head and neck cancer (SCCHN) previously treated or not with PD-(L)1 inhibitors (IO): 1-year survival data.
Presenter: Roger Cohen
Session: Poster Display session 3
Resources:
Abstract
4703 - Updated results of a phase II study evaluating accelerator-based boron neutron capture therapy (AB-BNCT) with borofalan(10B) (SPM-011) in recurrent squamous cell carcinoma (R-SCC-HN) and recurrent and locally advanced non-SCC (R/LA-nSCC-HN) of the head and neck
Presenter: Katsumi Hirose
Session: Poster Display session 3
Resources:
Abstract
3638 - Phase 3 KEYNOTE-048 Study of First-Line (1L) Pembrolizumab (P) for Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC): Asia vs Non-Asia Subgroup (subgrp) Analysis
Presenter: Makoto Tahara
Session: Poster Display session 3
Resources:
Abstract
2954 - Integrated data review evaluating safety, pharmacokinetics (PK) and immunogenicity of RM-1929 photoimmunotherapy (PIT) in subjects with locoregional, recurrent head and neck squamous cell carcinoma (rHNSCC).
Presenter: Jennifer Johnson
Session: Poster Display session 3
Resources:
Abstract
3629 - First line versus second line immunotherapy in recurrent/metastatic squamous cell carcinoma of the head and neck
Presenter: Caroline Even
Session: Poster Display session 3
Resources:
Abstract
767 - Sensitizing HRAS overexpressing head and neck squamous cell carcinoma (HNSCC) to chemotherapy
Presenter: Theodoros Rampias
Session: Poster Display session 3
Resources:
Abstract
4985 - A Single-Arm, Open-Label, Multicenter, Phase IIIb Clinical Trial with Nivolumab in Subjects with Recurrent or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck.
Presenter: Paolo Bossi
Session: Poster Display session 3
Resources:
Abstract
1564 - Long-term Results of Phase 2 Trial of Reduced Modified Clinical Target Volume in Low-risk Nasopharyngeal Carcinoma Treated with Intensity Modulated Radiotherapy
Presenter: Jingjing Miao
Session: Poster Display session 3
Resources:
Abstract
3356 - To compare two oral mucosa contouring methods in predicting acute oral mucocitis in nasopharyngeal carcinoma treated with helical tomotherapy
Presenter: Yuan-Yuan Chen
Session: Poster Display session 3
Resources:
Abstract
1984 - Induction chemotherapy (IC) followed by concurrent chemoradiotherapy (CCRT) in nasopharyngeal carcinoma (NPC)
Presenter: Gizem Kaval
Session: Poster Display session 3
Resources:
Abstract